Spastazoline

CAS No. 2351882-11-4

Spastazoline( —— )

Catalog No. M21959 CAS No. 2351882-11-4

Spastazoline is a potent and selective inhibitor of spastin(Human spastin with IC50 of 99 nM ).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 71 In Stock
5MG 65 In Stock
10MG 107 In Stock
25MG 216 In Stock
50MG 317 In Stock
100MG 455 In Stock
200MG 631 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Spastazoline
  • Note
    Research use only, not for human use.
  • Brief Description
    Spastazoline is a potent and selective inhibitor of spastin(Human spastin with IC50 of 99 nM ).
  • Description
    Spastazoline is a potent and selective inhibitor of spastin(Human spastin with IC50 of 99 nM).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    spastin
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2351882-11-4
  • Formula Weight
    382.51
  • Molecular Formula
    C20H30N8
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:95 mg/ml(248.36 mM; Need ultrasonic)
  • SMILES
    CC(C)[C@@H]1CN(CCN1)c1nc(Nc2cc([nH]n2)C(C)(C)C)c2cc[nH]c2n1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Cupido T, et al. Designing a chemical inhibitor for the AAA protein spastin using active site mutations. Nat Chem Biol. 2019 Feb 18.2. Pisa R , Cupido T , Steinman J B , et al. Analyzing Resistance to Design Selective Chemical Inhibitors for AAA Proteins[J]. Cell Chemical Biology, 2019, 26(9).
molnova catalog
related products
  • Fmoc-Thr(GlcNAc(Ac)3...

    This amino acid is compatible with standard protocols in Fmoc solid phase peptide synthesis. Following chain assembly.

  • Pancreatic Polypepti...

    Pancreatic Polypeptide (31-36) (human)

  • VULM 1457

    VULM 1457 is a potent ACAT inhibitor. VULM 1457 has remarkable hypolipidaemic activity and improves the overall myocardial ischaemia-reperfusion injury outcomes.